Neurobiology of Mild Cognitive Impairment in the Elderly

描述（由申请人提供）：题为“老年人轻度认知障碍的神经生物学”的项目正在进入第十一个年头。该项目的总体目标是确定阿尔茨海默病发展前轻度认知障碍的老年人认知下降网络的分子底物。为了实现这一目标，该计划汇集了来自芝加哥地区和大学以外的一些基础和临床科学家。该项目将设在芝加哥的拉什大学医学中心。该计划项目包括一个行政和组织分配核心和一个统计和数据管理核心。此外，以下四个研究项目完成了该计划：1：轻度认知障碍中的神经元缠结演变（Lester“Skip”Binder，西北大学医学中心，项目负责人）; 2）轻度认知障碍中的LR 11（Allan Levey，埃默里大学，项目负责人）; 3）胆碱营养性厌食症和轻度认知障碍（Elliott Mufson，项目负责人）;和4）突触、胆碱能和淀粉样蛋白缺失和轻度认知障碍（Steven DeKosky，匹兹堡大学项目1负责人）。每个核心将支持所有这些研究项目。此外，这些项目将收到来自NIA资助的Rush ADCC神经病理学和宗教秩序研究核心的临床数据和组织样本。该计划项目产生的数据结果将为轻度认知障碍老年人的神经生物学，向AD的过渡提供新的线索，并将促进AD阶段特异性疗法的转化发展。

DESCRIPTION (provided by applicant): The program Project entitled "Neurobiology of Mild Cognitive Impairment in the Elderly" is entering its eleventh year. The overall goal of the project is the determine the molecular substrate of the onet of cognitive decline in eldery people with mild cognitive impairment prior to the development of frant Alzheimer's disease. To accomplish this goal the program brings together a number of basic and clinical scientists from the Chicago area and outside universities. The project will be based at Rush University Medical Center in Chicago. The Program Project consists of an Administrative and Tissue distribution Core and a Statistics and Data Management Core. In addition the following four research projects complete the program: 1: Neurofibrillary Tangle Evolution in Mild Cognitive Imapairment (Lester "Skip" Binder, Northwestern University Medical Center, project leader); 2) LR11 in Mild Cognitive Impairment (Allan Levey, Emory University, project leader); 3) Cholinotrophic Abnormalities and Mild Cognitive Impairment (Elliott Mufson, Project Leader); and 4) Synaptic, Cholinergic and Amyloid Abnormalities and Mild Cognitive impairment (Steven DeKosky, University of Pittsburgh project 1 Leader). Each core will support all of these research projects. Moreover, these projects will receive clinical data and tissue samples from the NIA funded Rush ADCC Neuropahtology and Religious Orders Study Cores for all projects. The results of the data produced by the Program Project will shed new light on the neurobiology of elderly people with mild cognitive impairmnent, the transistion to AD and are will facilitate the translational development of stage-specific therapies for AD.